Dr Tommy Dolan is Vice President at Pfizer in Worldwide Pharmaceutical Sciences and is also the Pfizer Sandwich Site Head.
Tommy began his career at Pfizer in 1990 as a formulation scientist in the Pharmaceutical R&D Department. He held various positions in Pharmaceutical R&D, leading groups involved in a broad spectrum of drug delivery technologies and products across all stages of development. Tommy was appointed head of the UK Pharmaceutical R&D department in 2002. In 2005 he moved to head the UK Analytical R&D department before leading the Inhalation and Devices Centre of Emphasis at the beginning of 2007 through to 2011. Since joining Pfizer he has held various matrix leadership roles in Pharmaceutical Sciences including Viagra Pharmaceutical Sciences team leader, UK Pharmaceutical Sciences Exploratory Development Lead, Product Enhancement Lead and Global Materials Science lead. He lead the Enablex (darifenacin) oral controlled release team responsible for design of the patented controlled release marketed dosage form.
Prior to joining Pfizer, Tommy completed his undergraduate and postgraduate education in Pharmacy at the University of Strathclyde studying novel drug carriers in the treatment of Visceral Leishmaniasis. Following a period of post doctoral study in immunology at the Universities of Strathclyde and Glasgow he joined Controlled Therapeutics UK Ltd. researching novel hydrogels as drug delivery systems.
He is a past Chair of the UK Academy of Pharmaceutical Sciences, a member of the UK Academy of Pharmaceutical Sciences Advisory Board, a visiting Professor at the School of Pharmacy University College London, a member of the UK Medicines Manufacturing Industry Partnership (MMIP) Steering Group, and a Company Director on the Pfizer UK Ltd Board. He also holds a D.Sc. (honoris causa) from the University of Greenwich.